ALS Ice Bucket Challenge Returning This August
Co-founders Pat Quinn and Pete Frates will kick off this year’s ALS Ice Bucket Challenge on July 31 in Boston. Read more here.…
Trial News & Events
Steve Gleason Act scores victory for ALS patients on Capitol Hill
Steve Gleason’s latest remarkable achievement will soon be headed to the desk of President Barack Obama. Read more here.…
The ALS Association Announces $11.6 Million in New Research Grants to Find Treatments and a Cure for
The research awards announced today include investigator-initiated grants, drug development contracts, Milton Safenowitz Postdoctoral Fellowships and support of the NEALS/TREAT ALS™ Clinical Trials Network. Read more here.…
Ice Bucket Challenge Brings $1.5 Million for ALS Drug Trial
Cytokinetics Inc. said it received $1.5 million to help finance testing of an experimental drug to improve lung function in patients with the devastating neurodegenerative disorder. Read more here.…
New Clinical Pilot Studies Will Use Biomarkers to Speed Therapy Development
The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative. Read more here.…
Mitsubishi Tanabe Pharma announces use of RADICUT for treating ALS patients in Japan
Mitsubishi Tanabe Pharma Corporation issued a press release on June 26 announcing that it had received approval to use RADICUT (Edaravone) in treating patients with ALS in Japan. The announcement comes after a series of clinical trials in Japan were said to demonstrate that patients receiving the drug showed less functional loss than patients receiving a placebo. We look forward to seeing the data supporting approval in Japan. Read press release here.…
DREAM ALS Stratification Prize4Life Challenge
Prize4Life, Sage Bionetwroks and DREAM are proud to anounce the launch of The DREAM ALS Stratification Prize4Life Challenge. The prize, is a computational challenge inviting bioinformatics, statisiticians, computation geeks and math geniuses to work on the PRO-ACT database and identify meaningful subgroups of ALS patients. The challenge offers a $28000 prize and journal partnership with Nature Biotechnology. Read more here.…
Dr. Maragakis on Q Therapeutics’ FDA Clearance for Clinical Trials with Q-Cells in Patients with ALS
Dr. Nicholas Maragakis, professor at Johns Hopkins University School of Medicine and NEALS member, was a key contributor to the pre-clinical development of Q-Cells. Read what he has to say about this research opportunity. Q Therapeutics announced clearance of its investigational new drug application for phase 1/2a clinical trials with Q-Cells in patients with ALS on June 4, 2015. Dr. Nicholas Maragakis, professor at Johns Hopkins University School of Medicine and NEALS member, was a key contributor to the pre-clinical development of Q-Cells. “This has been an amazing opportunity to be a part of the pre-clinical…
Nominate PALS for the 5th Annual ALS CRLI
NEALS is now accepting nominations for the 2015 ALS Clinical Research Learning Institute in Clearwater Beach, Florida from November 6 - 7, 2015. Learn more about the CRLI and the nomination process. The Northeast ALS Consortium (NEALS) is seeking nominations and self-nominations for this year’s ALS Clinical Research Learning Institute. The ALS Clinical Research Learning Institute, sponsored by the ALS Association’s TREAT ALS initiative, is an intensive two day program dedicated to educating attendees on clinical research and therapy development and empowering this group to be advocates for ALS clinical research. Patients and patient-caregiver pairs…
Neurodegeneration in C. elegans models of ALS requires TIR-1/Sarm1 immune pathway activation in neur
Here we show that the expression of mutant proteins causative for ALS in Caenorhabditis elegans motor neurons induces an innate immune response via TIR-1/Sarm1. Read more here.…